Therapeutics utilizing access via the “brake” technology and treatment through the gut, Therabrake is aiming to treat Alzheimer’s disease as a metabolic disease progression.
- Technology Presenter: Jerome J Schentag, Founder and CEO
- Accelerator-Commercial Catalyst:Caroline Hoedemaker
- Defined Milestone: Examine Alzheimer’s as a separately treatable disease from the “Brake” technology
- Targeted Completion: 1 month